Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan

Respiration

Volumn 75, Issue 2, 2008, Pages 211-214

  Foley, Raymond J ^a   Metersky, Mark L ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Bosentan; Endothelin 1; Pulmonary hypertension; Sarcoidosis

Indexed keywords

BOSENTAN; HYDROCHLOROTHIAZIDE; PREDNISONE;

ADULT; AIRWAY PRESSURE; ARTERIAL GAS; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DYSPNEA; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HUMAN; LUNG FUNCTION TEST; MALE; OXYGEN THERAPY; PHYSICAL EXAMINATION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SARCOIDOSIS; THORAX RADIOGRAPHY;

ANTIHYPERTENSIVE AGENTS; ENDOTHELIN-1; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS, PULMONARY; SULFONAMIDES;

EID: 40549129005     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089815     Document Type: Article

References (20)

1. Preston IR, Klinger JR, Landzberg MJ, et al: Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001;120: 866-872.
2. Smith LJ, Lawrence JB, Katzenstein AA: Vascular sarcoidosis: a rare cause of pulmonary hypertension. Am J Med Sci 1983;285:38-44.
3. Battesti JP, Georges R, Basset F, et al: Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978;33:76-84.
4. Rodman DM, Lindenfeld J: Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 1990;97:500-502.
5. Gluskowski J, Hawrylkiewicz I, Zych D, et al: Effects of corticosteroid treatment on pulmonary hemodynamics in patients with sarcoidosis. Eur Respir J 1990;3:403-407.
6. Jones K, Higenbottam T, Wallwork J: Pulmonary vasodilatation with prostacyclin in primary and secondary pulmonary hypertension. Chest 1989;96:784-789.
7. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
8. Simonneau G, Barst RJ, Galie N, et al: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804.
9. Rubin LJ, Badesch DB, Barst RJ, et al: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
10. American College of Chest Physicians Annual Meeting, Seattle, 2004.
11. Badesch DB, Abman SH, Ahearn GS, et al: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
12. D'Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-349.
13. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-1482.
14. McLaughlin VV, Sitbon O, Rubin LJ, et al: The effect of fi rst-line bosentan on survival of patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2003;167:A442.
15. Shorr AF, Darcy BD, Nathan SD: Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002;122:233-238.
16. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1998;332:411-415.
17. Clozel M: Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefi t? Ann Med 2003;35:605-613.
18. Giaid A, Yanagisawa M, Langleben D, et al: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739.
19. Reichenberger F, Schauer J, Kellner K, et al: Different expression of endothelin in the bronchoalveolar lavage fl uid of patients with pulmonary diseases. Lung 2001;179:163-174.
20. Letizia C, Danese A, Reale MG, et al: Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 2001;43:257-261.